tbuckley/cabot-search huggingface dataset:
Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients.
Authors: Y Bastion, C Sebban, F Berger, P Felman, G Salles, C Dumontet, P A Bryon, B Coiffier
Journal: Journal of Clinical Oncology (1997)

PURPOSE To assess the incidence of lymphoma transformation in the natural history of follicular lymphoma (FL) patients and the factors that are predictive of this event. PATIENTS AND METHODS Two hundred twenty patients with FL treated in our institution between 1975 and 1990, with a median follow-up duration of 9 years, were included in this retrospective analysis. RESULTS Transformation was proven by histology in 34 patients or by cytology in 13 patients and was considered as highly probable on clinical arguments in five patients for an overall incidence of 24%. The probability of transformation was 22% at 5 years and 31% at 10 years and tended to plateau after 6 years. Predictive factors for transformation were nonachievement of complete remission (CR) after initial therapy (P &lt; 10(-4), low serum albumin level (&lt; 35 g/L) (P = .001), and beta 2-microglobulin level greater than 3 mg/L (P = .02) at diagnosis. In a multiparametric analysis, only beta 2-microglobulin level retained prognostic significance for freedom-from-transformation (FFT) survival (P = .04). Transformation accounted for 44% of deaths and was associated with a poor outcome, with a median survival time of 7 months. CONCLUSION Transformation is an early event in the course of the disease and is mainly observed in patients with known adverse prognostic factors or those who do not achieve CR after initial treatment. These findings may be useful to select follicular lymphoma patients for intensive therapeutic approaches.
Pragmatic randomised controlled trial to evaluate guidelines for the management of infertility across the primary care-secondary care
Authors: J. Morrison
Journal: BMJ (2001)

<h3>Abstract</h3> <b>Objective:</b> To investigate the effect of clinical guidelines on the management of infertility across the primary care-secondary care interface. <b>Design:</b> Cluster randomised controlled trial. <b>Setting:</b> General practices and NHS hospitals accepting referrals for infertility in the Greater Glasgow Health Board area. <b>Participants:</b> All 221 general practices in Glasgow; 214 completed the trial. <b>Intervention:</b> General practices in the intervention arm received clinical guidelines developed locally. Control practices received them one year later. Dissemination of the guidelines included educational meetings. <b>Main outcome measures:</b> The time from presentation to referral, investigations completed in general practice, the number and content of visits as a hospital outpatient, the time to reach a management plan, and costs for referrals from the two groups. <b>Results:</b> Data on 689 referrals were collected. No significant difference was found in referral rates for infertility. Fewer than 1% of couples were referred inappropriately early. Referrals from intervention practices were significantly more likely to have all relevant investigations carried out (odds ratio 1.32, 95% confidence interval 1.00 to 1.75, P=0.025). 70% of measurements of serum progesterone concentrations during the midluteal phase and 34% of semen analyses were repeated at least once in hospital, despite having been recorded as normal when checked in general practice. No difference was found in the proportion of referrals in which a management plan was reached within one year or in the mean duration between first appointment and date of management plan. NHS costs were not significantly affected. <b>Conclusions:</b> Dissemination of infertility guidelines by commonly used methods results in a modest increase in referrals having recommended investigations completed in general practice, but there are no detectable differences in outcome for patients or reduction in costs. Clinicians in secondary care tended to fail to respond to changes in referral practice by doctors. Guidelines that aim to improve the referral process need to be disseminated and implemented so as to lead to changes in both primary care and secondary care. <h3>What is already known on this topic</h3> Most previous research into clinical guidelines has focused on their development and implementation Evidence is lacking about the outcomes and costs associated with the use of clinical guidelines <h3>What this study adds</h3> Clinical guidelines that may alter the balance of care between general practice and hospital settings require more intensive implementation than guidelines aimed at either setting on its own The cost effectiveness of clinical guidelines should not be assumed
Morbidity in Adult Parathyroid Surgery
Authors: A G A Cowie
Journal: Journal of the Royal Society of Medicine (1982)

The results of surgery in a series of 700 consecutive cases of primary and tertiary hyperparathyroidism are reported with especial reference to mortality and morbidity. Providing that the operation is a first or second operation and that the patient is below 70 years of age, the operation has been found to be safe and uncomplicated.
A European treatment protocol for bone sarcoma in patients older than 40 years
Authors: S. Ferrari, S. Smeland, S. Bielack, A. Comandone, P. Dileo, P. Picci, K. Sundby Hall, M. Eriksson, H. Honegger, P. Reichardt
Journal: Journal of Clinical Oncology (2009)

10516 Background: EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S.) is the first prospective multicenter international study for patients 41 - 65 years old with high-grade bone sarcoma. Methods: Patients with HG Osteosarcoma (OS), HG sarcoma NOS (S), Fibrosarcoma, MFH, Leiomyosarcoma, Dedifferentiated Chondrosarcoma (DCh) were included. Chemotherapy: Combinations of cisplatin/doxorubicin (CDP 100mg/m2/ADM 60mg/m2), ifosfamide/CDP(IFO 6g/m2/CDP 100mg/m2) and IFO/ADM (IFO 6g/m2/ADM 60mg/m2) were repeated three times (9 cycles). Surgery was planned after 3 cycles. Methotrexate (8g/m2) was postoperatively added in poor responders. Immediate surgery was allowed and 9 cycles with CDP, ADM, IFO were postoperatively given. Results: In December 2007, 140 patients were registered (median age 51 years). OS (51%), S (16%), and DCh (11%) were the more frequent histotypes. Synchronous metastases in 30 (21%) patients, central location of tumor in 45 (32%). Surgical complete remission (SCR) was achieved in 84% of patients, (localized 91%, metastatic 37%) without difference among the histology groups. One surgical-related and one chemotherapy-related death were reported. Grade 4 WBC and PLT incidence was 55% and 17%.Renal toxicity and peripheral neurotoxicity were reported in 16% and 20% of patients. With a median follow-up of 25 months (4–68) 3 year OS was 58% (95%CI 48–68%) [7% (95%CI 0–19%) without SCR]. In patients with SCR, 3 year OS and EFS were 46% (95%CI 9–83%) and 0% in case of synchronous metastases and 69% (95%CI58–80%) and 45% (95%CI33–57%) for localized patients; 50% (95%CI 29–71%) and 40% (95%CI 20–59%) for patients with central tumor, 73% (95%CI61–85%) and 44% (95%CI31–57%) for those with extremity tumor; 68% (95%CI 52–83%) and 46% (95%CI 32–54%) for OS, 64% (95%CI 42–85%) and 48% (95%CI 25–71%) for S, 48% (95%CI 13–82%) and 27% (95%CI 1–54%) for DCh. Conclusions: The protocol is feasible, but the chemotherapy-related toxicity is remarkable. Surgical complete remission is the main factor influencing survival. Central location and synchronous metastases are negative prognostic factors, but 50% 3-year OS can be achieved with aggressive local and systemic treatment. Osteosarcoma and high-grade sarcoma NOS benefit from chemotherapy more than patients with dedifferentiated chondrosarcoma. No significant financial relationships to disclose.
Outcome of Radiation-Related Osteosarcoma After Treatment of Childhood and Adolescent Cancer: A Study of 23 Cases
Authors: Marie-Dominique Tabone, Philippe Terrier, Hélène Pacquement, Maud Brunat-Mentigny, Claudine Schmitt, Annie Babin-Boilletot, Hazem H. Mahmoud, Chantal Kalifa
Journal: Journal of Clinical Oncology (1999)

PURPOSE: We analyzed the clinical features and outcome of patients with radiation-associated osteosarcoma treated during the era of contemporary chemotherapy. PATIENTS AND METHODS: The characteristics and outcome of 23 patients (17 males and six females) treated during childhood or adolescence for a solid tumor who later developed osteosarcomas within the radiation field between 1981 and 1996 were reviewed. RESULTS: The median dose of radiation delivered to the first cancer was 47 Gy. Nineteen patients also received chemotherapy. The median time between radiotherapy and the diagnosis of secondary osteosarcoma was 8 years. Histologic slide review showed conventional central osteosarcoma with various differentiation patterns in 21 cases, together with one case of high-grade surface osteosarcoma and one of periosteal osteosarcoma. The sites of involvement were the craniofacial bones in six cases, the first cervical vertebra in one, the girdle bones in seven, and the extremities of long bones in nine. Three patients had metastatic disease at the diagnosis of osteosarcoma. Palliative therapy was administered to seven patients. The aim of treatment was curative for 16 patients, two of whom underwent amputation without further therapy. Intensive chemotherapy regimens were administered to 14 patients before and/or after surgery. Fifteen patients achieved complete surgical remission. Twelve patients were alive and disease-free at a median follow-up duration of 7.5 years. Overall and event-free survivals at 8 years were 50% and 41%, respectively. CONCLUSION: Patients with radiation-related osteosarcoma and resectable lesions can be cured with surgery and intensive preoperative and postoperative chemotherapy.
The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection
Authors: T.-F. Tsai, V. Ho, M. Song, P. Szapary, T. Kato, Y. Wasfi, S. Li, Y.K. Shen, C. Leonardi
Journal: British Journal of Dermatology (2012)

Ustekinumab is a monoclonal antibody that targets interleukin (IL)-12/23 p40 to treat psoriasis. The IL-12 pathway is also important in regulating immunity to Mycobacterium tuberculosis.To evaluate the safety of isoniazid (INH) prophylaxis for newly identified latent tuberculosis infection (LTBI) in ustekinumab-treated patients with psoriasis.Safety data from 3177 psoriasis patients evaluated across five phase III trials of ustekinumab (45 or 90 mg) conducted in North America, Europe and Asia were analysed. LTBI was diagnosed based on positive tuberculin skin test or QuantiFERON(®) -TB test (Cellestis, Carnegie, Vic., Australia) without evidence of active tuberculosis.At baseline, 101/2898 (3·5%) non-Asian and 66/279 (23·7%) Asian patients were newly identified with LTBI, and all were treated with INH. Through week 12, among patients who received INH, rates of adverse events (AEs) representative of INH toxicity were generally comparable between control and ustekinumab-treated patients, as well as between ustekinumab dose groups. Markedly abnormal alanine transaminase values occurred with comparable incidences between control and ustekinumab-treated patients. The rate of study agent discontinuation due to INH toxicity was low (5/167, 3·0%) and comparable between control and ustekinumab groups through week 12. The rate of INH-related AEs did not increase disproportionately through week 28. No cases of active tuberculosis were reported in patients who received concomitant INH starting at baseline.Across five trials of ustekinumab-treated patients with psoriasis, no cases of LTBI reactivation were observed in patients receiving concomitant INH prophylaxis for LTBI. INH prophylaxis was generally well tolerated by these patients with psoriasis.
Carcinogenicity of Camellia sinensis (Tea) and Some Tannin-Containing Folk Medicinal Herbs Administered Subcutaneously in Rats23
Authors: Govind J. Kapadia, B. D. Paul, E. B. Chung, B. Ghosh, S. N. Pradhan
Journal: JNCI Journal of the National Cancer Institute (1976)

In an attempt to correlate the high incidence of esophageal carcinoma in natives of certain places with their habit of using herbaceous folk medicines, we performed bioassays of several plant extracts and the fractions prepared from them. Fourteen extracts and fractions from 6 plants were injected sc into NIH Black rats. The tannin fractions from Quercus falcata pagodaefolia, Diospyros virginiana, and Camellia sinensis were very active and produced tumors at the injection site in 66% or more of the treated animals. Tannin fractions from 3 other plants and total aqueous extracts from 5 of 6 tested plants were also tumorigenic in rats. The induced tumors were malignant fibrous histiocytomas similar, if not identical, to those encountered in humans. The experiment indicated a possibility of induction of tumor in man by the tested plant materials.
XELOX (capecitabine and oxaliplatin) as 1<sup>st</sup> line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC)
Authors: A. Salud, P. Escudero, J. Feliú, L. López-Gómez, M. Bolaños, A. Galán, A. Yubero, J. M. Vicent, F. Losa, M. González Barón
Journal: Journal of Clinical Oncology (2005)

3620 Background: XELOX is a highly active combination in 1st line MCRC, comparable to FOLFOX with less neutropenia and a convenient 3-weekly cycle length. As a well-tolerated, more home-based therapy, XELOX merits investigation in a more elderly pt population. Methods: Objectives of this phase II study were response rate (RR), safety profile, time to progression, overall survival and clinical benefit after XELOX chemotherapy as 1st line treatment in pts aged ≥ 70 years with histologically proven MCRC. Selection criteria included no prior chemotherapy (except adjuvant therapy), measurable disease according to RECIST, ECOG PS ≤ 2 and adequate bone marrow, renal and hepatic functions. Patients received oxaliplatin 130mg/m2 i.v. D1 followed by oral capecitabine 1000 mg/m2 twice daily for 14 days (750 mg/m2 if Cr Cl=30–50 ml/min) every 3 weeks. Toxicity was evaluated using WHO toxicity criteria. Results: 50 pts were evaluated for safety: M/F, 36/14, median age 75 years (70–82), ECOG PS 0/1: 54%/46%. 90.3% pts had no comorbidity, 90.2% had mild dependence on help (Barthel Index) and most (M/F 70.0%/63.6%) were autonomous (Lawton Index). Median number of metastatic sites was 1 (1 site 78.7%), in liver (68.1%), lung (34%) and nodes (12.8%). A total of 227 cycles have been administered: median 4.5 (1–8). Median relative dose intensity 92% for oxaliplatin and 98%/86% (Cr Cl ≤50/Cr Cl >50 ml/min, respectively) for capecitabine. Intent-to-treat efficacy analysis: 5 pts achieved CR, 13 PR, 12 SD, 14 PD and 6 NE (3 toxicity, 1 exitus, 1 lost of follow-up, 1 consent withdrawal) RR: 36% (95% CI: 22.7–49.3). With a median follow-up of 7.5 months, median TTP was 6.9 (95% CI: 4.8–9) months. There was 1 treatment-related death: diarrhea and asthenia. Conclusions: XELOX seems to be effective and well tolerated in 1st line treatment of elderly pts with MCRC. No significant financial relationships to disclose.
The validity of the distinction between bulimia with and without anorexia nervosa
Authors: David M. Garner, Paul E. Garfinkel, Martha O'Shaughnessy
Journal: American Journal of Psychiatry (1985)

The purpose of this study was to examine the relationship between bulimia in women with anorexia nervosa and bulimia of a similar severity in normal-weight women and to determine the support for the distinction between these two groups according to DSM-III criteria. Results indicated that bulimic women with anorexia nervosa (N = 59) and bulimic normal-weight women (N = 59) resembled each other on most variables and were more similar to each other than to women with anorexia nervosa who rigidly restricted food intake (N = 59). The results failed to support the diagnostic distinction between bulimia in anorexic women and bulimia of equal severity in normal-weight women.
Acceptance of Lesbian, Gay, Bisexual, and Transgender People
Authors: Olivier Colin
Journal: JAMA Neurology (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Role of TRPC6 channel in eosinophil function
Authors: Akiko Sano, Hiroyuki Sano, Takashi Iwanaga, Yuji Tohda
Journal: European Respiratory Journal (2013)

[  Objective  ]   Calcium homeostasis plays a key role in the regulation of many functional responses such as degranulation, lipid mediator release in airway inflammatory cells, including eosinophils. The transient receptor potential canonical (TRPC) channels are known as a subfamily of nonselective cation channels permeable to Ca 2+ , and thought to have a significant role in airway inflammation. Among the TRPC channels, TRPC6 expression has been demonstrated in human eosinophils. The objective of this study was to examine the role of TRPC channel in Ca 2+  signaling and eosinophil degranulation.   [  Methods  ]   Eosinophils were isolated from human peripheral blood of mildly atopic donors by a modification of the negative selection immunomagnetic separation technique. Detection of TRPC6 protein in human eosinophils was performed using Western blot analysis. Eosinophil peroxidase release was measured by enzyme assay. Intracellular Ca 2+  concentration was measured fluorometrically with Fluo3-AM loaded eosinophils as previously described.   [  Result  ]   A TRP family member, TRPC 6 expression was detected in human eosinophils byWestern blotting. Application of FMLP caused a transient increase in intracellular Ca 2+  concentration and that was decreased when cells were preincubated with TRP channel inhibitor, SKF96365. FMLP- induced EPO release was also inhibited by SKF96365.   [  Conclution  ]   Our data demonstrate that TRP channel inhibitor, SKF96365, inhibited the FMLP-induced intracellular Ca 2+  increase and eosinophil degranulation. TRP6 may have profound effect on the regulation of eosinophil functional responses through the Ca 2+ influx pathway.
Magnetic resonance imaging in the staging of solitary plasmacytoma of bone.
Authors: L A Moulopoulos, M A Dimopoulos, D Weber, L Fuller, H I Libshitz, R Alexanian
Journal: Journal of Clinical Oncology (1993)

To assess prospectively the role of magnetic resonance (MR) imaging in the staging of patients with a solitary bone plasmacytoma (SBP).Twelve consecutive patients with an apparent SBP underwent MR imaging of both the primary tumor and the thoracic and lumbosacral spine to seek additional foci of marrow involvement that might have been undetected by standard skeletal survey. All patients received megavoltage irradiation (total dose, 40 Gy) to the primary lesion.MR imaging of the thoracic and lumbosacral spine showed additional foci of marrow replacement in four of 12 patients, with signal characteristics identical to those of the primary tumor. In all four patients, the abnormal protein persisted at greater than 50% of the pretreatment value following radiation treatment. In contrast, the myeloma protein disappeared or was reduced by greater than 50% in five of the six patients with secretory disease and without additional marrow abnormalities. One of four patients progressed to multiple myeloma 10 months after diagnosis with new lesions on conventional radiographs in the same areas as detected previously by MR imaging.Four of 12 patients considered to have a SBP by standard criteria may have been understaged, because MR imaging showed additional marrow abnormalities consistent with myeloma. MR imaging of the spine may contribute to the initial staging of SBP, especially since some patients may be cured with radiotherapy.
Lung diffusing capacity for CO and NO in elderly with 'senile' or 'juvenile' pulmonary phenotype: Results from the KORA-Age study
Authors: Stefan Karrasch, Jürgen Behr, Joachim Heinrich, Rudolf M. Huber, Dennis Nowak, Annette Peters, Rudolf A. Jörres, Holger Schulz
Journal: European Respiratory Journal (2014)

Background:  Even in lung-healthy individuals the age-related decline of spirometrically determined lung function is subject to considerable inter-individual variability. Our study examined the relationship between spirometric indices and parameters of gas exchange in older age.   Methods:  From a population-based sample from the Augsburg region (n=935, 65-90y) we selected two anamnestically lung-healthy subgroups with either poor (9senile9, n=84) or favourable (9juvenile9, n=74) FEV 1  percent predicted. Haemoglobin (Hb), diffusing capacity for CO (DLCO, corrected for Hb) and NO (DLNO) and alveolar volume (VA) were determined by single breath technique (CareFusion, Hoechberg).   Results:  Overall, there was a decline with age in Hb, VA, and the volume-related diffusing coefficients DLCO/VA and DLNO/VA (p   Conclusion:  These results confirm a decline of diffusing capacity up to an old age in anamnestically lung-healthy subjects. They indicate that a limitation of spirometrically determined lung function is associated with alterations in diffusing capacity due to a shift in the relationship between its two determinants pulmonary capillary blood sheet and alveolo-capillary membrane conductivity.   Supported by German Federal Ministry of Education and Research (BMBF FKZ 01ET0713) as part of the 9Health in old age9 program and the Competence Network ASCONET, subnetwork COSYCONET (BMBF FKZ 01GI0882).